A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome

Trial Profile

A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ADX 102 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to an Aldeyra Therapeutics media release, data from this trial are expected in September 2017.
    • 18 Jul 2017 According to an Aldeyra Therapeutics media release, last patient has been dosed.
    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting,according to an Aldeyra Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top